Landersdorfer, C.(1), C. M. J. Kirkpatrick(2), M. Kinzig-Schippers(1), J. Bulitta(1), U. Holzgrabe(3), F. Sörgel(1,4) New Insights into the Most Commonly Studied Drug Interaction with Antibiotics: Pharmacokinetic Interaction between Ciprofloxacin, Gemifloxacin and Probenecid at Renal and Non-renal Sites
|
Hennig, S. (1,2), Waterhouse T.(1) Wainwright C.(3), Bell S.(4), Miller H. (2), Charles B.(1) and Duffull S.(1) A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis
|
Plock, N.(1), C. Buerger(1), K. Kuester(1), C. Joukhadar(2), S. Kljucar(3), C. Kloft(1,4) A Population Pharmacokinetic Model for the Simultaneous Description of Linezolid Tissue and Plasma Disposition in Healthy Volunteers and Septic Patients
|
Zandvliet, Anthe S.(1), Alwin D.R. Huitema (1), William Copalu (2), Yasuhide Yamada (3), Tomohide Tamura (3), Jos H. Beijnen (1,4) , Jan H.M. Schellens (4,5) Pharmacogenetically guided dosing of the anticancer agent indisulam normalizes the risk of severe hematological toxicity
|
William Faltaos, D (1), S. Urien (1), V.Morel (2), G. Kaloshi (3), k. Hoang Xuan (3), V.Leblond (2), Philippe Lechat (1). Population pharmacokinetic study of methotrexate in patient with lymphoid malignancy
|
Yim, Dong-Seok (1), Dong-Gun Lee, Su-Mi Choi, Wan-Shik Shin, Hyon-oh Lah(1) Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea
|
Joerger, M., A.D.R. Huitema, V. D. Doodeman, H. Boot, R. W. Sparidans, J.H. Beijnen, J.H.M. Schellens Epirubicin pharmacokinetics-pharmacodynamics and metabolic pathway-associated gene polymorphisms: Significant influence of the novel UDP-glucuronosyltransferase 2B7 promoter mutation -66T>C
|
Tajima, Takeshi(1), Akihiro Yokoi (1), Peiming Ma (2), Ryosei Kawai (1) Population approach to assess the relationship of cyclosporin exposure and renal dysfunction in Japanese patients with rheumatoid arthritis
|
van Hest, Reinier1, Teun van Gelder1,2, Arnold Vulto1, Leslie Shaw3, Ron Mathôt1 Pharmacokinetic modeling of plasma protein binding of mycophenolic acid in renal transplant recipients
|
Verbeke, Geert Mixed models for the analysis of categorical repeated measures
|
Matthews, Ivan (1), Smith, Fang Gao (2), Aarons, Leon (1) Pharmacokinetics of a single bolus of propofol in Chinese children of different ages
|
Testart, D.(1), G. Blanc(2), P. Delrat(1), T. Shepard(1) Development of a tool to simulate intra-individual variability encountered in animals from standard preclinical toxicological study
|
Friberg, Lena E.(1), An M. Vermeulen(2), Mats O. Karlsson(1) A mechanism-based pharmacokinetic-pharmacodynamic model of the time-course of prolactin following antipsychotic drug treatment
|
Miller, Raymond , Howard Bockbrader, Sunny Chapel. Comparision of Pregabalin and Gabapentin Pharmacodynamics in Patients with Refractory Partial Seizures.
|
Duffull, S B (1), G Graham (2), K Mengersen (3) Bayesian Estimation of Optimal Sampling Times for Pharmacokinetic Models
|
Mills, Richard (1,2), Kayode Ogungbenro (1) & Leon Aarons (1) Simultaneous fitting of the Minimal Model to IVGTT and Glucose Clamp Data
|
Marchand, M. (1), O. Petricoul (1), E. Fuseau (1), D. Bentley (2), D. Critchley (2) Extrapolation from preclinical PKPD data to clinical response, Application to a new antiepileptic medication (drug X)
|
Al Za’abi MA (1), Xiaonian X (2), Donovan T (3), Charles BG (1) Use of Routine Data for Determination of the Population Pharmacokinetics and Enteral Bioavailability of Phenytoin in Neonates and Infants with Seizures
|
Panhard, Xavière and Adeline Samson Extension of the SAEM algorithm for the estimation of Inter-Occasion Variability: application to the population pharmacokinetics of nelfinavir and its metabolite M8
|
Prins, K (1), B. Poland (1), V. Nicolas (2), H. Porchet (2), P. Scalfaro (2), R. Bruno (1) Modeling and Simulation of DEBIO-025 to Support Design of a Dose-Response Monotherapy Study in HIV-1 infected Patients
|
Gaynor, Clare (1), Dunne, Adrian (1) and Davis, John (2) Comparison of conventional In Vitro - In Vivo Correlation methodology with non-linear mixed effects modelling
|
Langdon G (1), Gueorguieva I (2), Aarons L (3), Karlsson MO (1) Linking preclinical and clinical whole body physiologically-based pharmacokinetic models with prior distributions in NONMEM
|
Cronier, D. (1,5), E. Grenier (2), M. Lecomte (3), V. Autier (3), B. Ladstetter (4), L. J. Aarons (5), and J.P. Boissel (1) Modelling of insulin secretion: from beta-cell physiology to sulphonylurea-mediated insulin secretion
|
Carlsson, Kristin C., Radojka M. Savic, Andrew Hooker, Mats O. Karlsson. Mixture models in NONMEM - how to find the individual probability of belonging to a specific mixture, and why this can be useful information
|
Lindbom, L.(1), K. Tunblad(1), L. McFadyen(2), E.N. Jonsson(1), S. Marshall(2), M. O. Karlsson(1) The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data
|
Gibiansky, Leonid, Marc R. Gastonguay R/NONMEM Toolbox for Simulation from Posterior Parameter (Uncertainty) Distributions
|
Silber, Hanna E., Maria C. Kjellsson and Mats O. Karlsson The likelihood ratio test appears robust to most residual error model misspecifications
|
Hamrén, Bengt(1), Elisabeth Björk (1), Mats O. Karlsson (2) Mechanism-based pharmacokinetic and pharmacodynamic modelling of tesaglitazar in type 2 diabetes patients
|
Boström, Emma, Ulrika S. H. Simonsson and Margareta Hammarlund-Udenaes In vivo blood-brain barrier transport of oxycodone in the rat – active influx and implications for PK/PD
|
Bogacka, Barbara (1) Maciej Patan (2) Efficient Sampling Windows for Parameter Estimation in Population Models
|
Vis, Peter (1), Vanitha Sekar (2), Erno van Schaick (1) and Richard Hoetelmans (3) Development and application of a population pharmacokinetic model of TMC114 in healthy volunteers and HIV-1 infected subjects after administration of TMC114 in combination with low dose ritonavir
|
Wallin, Johan E, Friberg Lena E., Karlsson Mats O. An Adaptive Dosing Tool For Etoposide Using Neutrophil Counts Based on a Semi-Physiological Model
|
Dokoumetzidis, Aris and Leon Aarons Direct application of Bayes theorem for the combination of population pharmacokinetic analyses.
|
Dansirikul, C. H.E. Silber, M.O. Karlsson Comparison of models for baseline
|
Bulitta, J.(1), T. P. Lodise(2), G. L. Drusano(3), M. Kinzig-Schippers(1), U. Holzgrabe(4), F. Sörgel(1,5) Bias and Uncertainty of Monte Carlo Simulations with Beta-Lactams
|
Hennig, S. (1,2), Wainwright, CE. (3), Bell, SC. (4), Miller, H. (2) Friberg, LE. (1) and Charles, BG. (1) Paediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients
|
Kuester, K(1), A. Kovar(2), B. Brockhaus(2), C. Kloft(1,3) Population Pharmacokinetic Analysis for Matuzumab (EMD 72000) – A Humanised EGFR-Targeted Monoclonal Antibody
|
Post, T.M.(1), J.I. Freijer (1), W. de Winter (1), B.A. Ploeger (1,2) Accurate Interpretation of the Visual Predictive Check in order to Evaluate Model Performance
|
Matthews, Ivan and Aarons, Leon A population pharmacokinetic model for s-warfarin: application of a mixture model to determine genotype/phenotype.
|
Djebli, Nassim 1, Pierre Marquet1,2, Yann Le Meur1,3, Annick Rousseau1,4 Population pharmacokinetics of sirolimus in adult renal transplant patients and Bayesian estimation of individual systemic exposure
|
Lovern, Mark R , Ginny Schmith, George Dukes, David McSorley Using a Placebo Response Model to Optimize Clinical Trial Designs for Irritable Bowel Syndrome (IBS) Therapies
|
Leary, Robert H. and Dunlavey, Michael Parallel Processing for Nonlinear Mixed Effects Modeling
|
Chantel, S.(1,2), P. Martin(1,2), P.Y. Petit (3), D. Massignon(4), X. Dode(1), P. Maire (5), R.W. Jelliffe(6), G. Aulagner(1,2) Pharmacokinetic variability of the absorption of enoxaparin used subcutaneously for venous thromboembolism prophylaxis
|
Dittberner, S.(1), V. Duval (2), A. Staab (2), H. Fuchs (2), M. Tadayyon (2), U. Graefe-Mody (2), H.G. Schaefer (2), U. Jaehde (1) Pre-Clinical PK/PD Modeling for a Dipeptidyl Peptidase-IV Inhibitor
|
Lehr, T. (1), A. Staab (2), C. Tillmann (2), D. Trommeshauser (2), A. Raschig (2), H.G. Schaefer (2), C. Kloft (1,3) Efficacy modelling of NS2330 in mild Alzheimer’s disease patients
|
Lehr, T.(1), A. Staab (2), C. Tillmann (2), D.Trommeshauser (2), A. Raschig(2), H.G. Schaefer (2), C. Kloft (1,3) Population pharmacokinetics of NS2330 and its major metabolite in Alzheimer’s disease patients
|
Valle M, Grasa E, Yritia M, Romero S,, Barbanoj MJ. Population Pharmacokinetic-Pharmacodynamic modelling of olanzapine effects on the electroencephalogram in healthy volunteers.
|
Dehez, Marion(1)(2)(3), Marylore Chenel(1), Roeline Jochemsen(1), Stéphanie Ragot(2) Population modeling approach of circadian blood pressure variations using ambulatory monitoring in dippers and non dippers
|
Zeumer, D., A. Staab, T. Lehr, C. Tillmann, K.-H. Liesenfeld, H. G. Schaefer PROPHET - A convenient and efficient environment for the use of NONMEM in a global pharmaceutical company
|
Bertrand, Julie, Emmanuelle Comets, France Mentré Detecting a gene effect in pharmacokinetic models: comparison of different methods
|
Holford, Nick, Carl Kirkpatrick, Steve Duffull NONMEM Termination Status is Not an Important Indicator of the Quality of Bootstrap Parameter Estimates
|
Lopez-Pintor E (1), Valenzuela B (1), Montesinos A (2), Martín-Villodre A (2), Casabó V.G (2) Population pharmacokinetics approach for salbutamol sulphate in rats
|
Edginton, A.N. (1), S. Willmann (1), M. Kleine-Besten (2) Use of a physiology-based whole-body population model to simulate the influence of anthropometric-, clearance-, and physiological-variance on the pharmacokinetics of drugs
|
Ortega, Ignacio , An Vermeulen, Vladimir Piotrovsky Concentration-response analysis of antipsychotic drug effects using an indirect response model
|
Lindbom, Lars(1), Justin J Wilkins(1), Nicolas Frey(2), Mats O Karlsson(1), E Niclas Jonsson(1,2) Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis
|
Olofsen, E. Using the Lasso to simultaneously identify the covariate and variance-covariance structures of nonlinear mixed-effects models
|
Roy Pierre, Annabelle Lemenuel-Diot, Marylore Chenel Is it possible to perform equivalent simulations with NONMEM and TS2?
|
Paccaly, A (1), Speth, H (2), Jensen, BK (1), Maas, J (2) Non-Linear Population Pharmacokinetic Model for Otamixaban in Healthy Male Subjects
|
Claret, L. (1), P. Girard (2), K.P. Zuideveld(3), K. Jorga (3), J. Fagerberg (3), R. Bruno (1) A longitudinal model for tumor size measurements in clinical oncology studies
|
Hempel, Georg; Lanvers-Kaminsky, Claudia; Ahlke, Elvira; Müller, Hans-J.; Würthwein, Gudrun; Boos, Joachim A Population Model Describing the Activity-time Course of Pegylated Asparaginase in Children
|
Marshall, Scott1, Mike K Smith1, Eugene Cox2,3 and Jaap Mandema2,4 Application of PK/PD modelling in the development eletriptan DR for the treatment of acute migraine and prevention of headache recurrence.
|
Tousset, E.(1), H. Figueiredo (2),M.P. Schneider(2),O. Bugnon(2), B.Vrijens (1) Relation between patients’ variable compliance and office blood pressure in treatment-resistant hypertension.
|
Comets, Emmanuelle(1) and Céline Verstuyft (2) Analysis of digoxin data using Non-Parametric Maximum Likelihood (NPML)
|
Prémaud, A(1), Van Guilder M (2), Armstrong VW (3), Weber LT(3), Ghandi A (2), Oellerich M (3), Tonshoff B (3), Jelliffe R (2), Marquet P (1), Rousseau A (1) Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in paediatric renal transplant recipients using a non-parametric approach.
|
Armendariz Y2, Caldes A2 , Colom H1, Gilvernet S2, Peraire C1, Domenech J1, Grinyó JM2, Wilkins J3, Karlsson M3. Population pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus
|
Fernández-Teruel C, Navarro-Fontestad MC, González-Álvarez I, Bermejo M, Casabo VG Sparse sampling designs: a new method for estimating the complete AUC and its standard error
|
Holford, Nick, Goonaseelan (Colin) Pillai, Sandip Roy, Andrej Skerjanec, Serge Cremers, William Collins, Jean-Louis Steimer Population pharmacokinetics of balicatib, a cathepsin K inhibitor
|
Holford, Nick, Goonaseelan (Colin) Pillai, Nitin Kaila, William Collins, Sandip Roy, Serge Cremers, Ulrich Trechsel, Florilene Bouisset, Jean-Louis Steimer PKPD model for cathepsin K inhibition with balicatib and changes in bone turnover biomarkers, in particular NTx
|
Nestorov, I.1, A. Munafo2, O. Papasouliotis2, J. Visich1 and M. Rogge1 Population modeling of the relationship between TACI Ig exposure and biomarker response in patients with rheumatoid arthritis (RA)
|
Hutmacher, Matthew M, Sriram Krishnaswami An extension of the indirect response models to ordered categorical pharmacodynamic data using latent variables
|
Hing, Jeremy(1), Juan Jose Perez-Ruixo(1), Kim Stuyckens(1), Peter Zannikos(1), Arturo Soto-Matos(2), César Picó(2), Antoine Yver(1) and Andrew Chow(1) Population PK/PD Modelling & Simulation of Hematological Toxicity of Trabectedin in Cancer Subjects
|
Gupta, M, K Wade, B Jayaraman, J Mondick, JS Barrett Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions
|
Quartino, Angelica L., Lena E. Friberg, Mats O. Karlsson A simultaneous analysis of the time course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic model
|
Dodds, M.G. (1), J.E. Visich(1), I. Nestorov(1), R. Overgaard(2), M.C. Rogge(1) Population pharmacodynamic model of the effects of recombinant human interleukin 21 on platelets in humans
|
Perez Ruixo, Juan Jose Optimizing the Design of Phase I Studies of Erythropoietin Receptor Agonist Through Mechanism-Based PK/PD Modeling and Simulation
|
Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(1), Jiménez Torres N.V.(2), Semi-mechanistic KPD model for haematological toxicity in breast cancer patients receiving high dose of chemotherapy
|
Nalda-Molina, R (1), Bermejo M. (2), Casabó V.G. (2) A simple physiological-pharmacokinetic model to simulate bioequivalence trials
|
Weatherley B., L. McFadyen, P. Milligan Population Analysis of Maraviroc Phase 1 Noncompartmental Pharmacokinetic Data
|
Nekka, Fahima (1,2), Caroline-E. Petit-jetté (1), Jun Li (1,2), Denis Gohore Bi (1), Renée Bergeron (3), Jérome del Castillo (4) Therapeutic modelling and analysis of random feeding features of feed-administered chlortetracycline
|
Wilkins, Justin J (1), Karlsson, Mats O (1), Jonsson, E Niclas (2) Patterns and power for the visual predictive check
|
Nielsen, Elisabet I(1), Uwe Ewald (2), Lena E Friberg (1) Population Pharmacokinetics of Gentamicin in Preterm and Term Newborn Infants
|
Hussein, Ziad(1), Brigitte Lacroix(2), Maria-Laura Sargentini-Maier(2) Population pharmacokinetics of the new antiepileptic drug brivaracetam
|